Genetically modified Poliovirus (PVS-RIPO) - Revision history

Lazy at 08:28, 18 January 2025

2025-01-18T08:28:55Z

← Older revision		Revision as of 01:28, 18 January 2025
Line 13:		Line 13:
	the more recent patients in the trial are being treated with a smaller dose than the trial		the more recent patients in the trial are being treated with a smaller dose than the trial
	originally started with. Read an interview with Darrel Bigner discussing this trial here.		originally started with. Read an interview with Darrel Bigner discussing this trial here.
	}}		\|overview=Genetically modified Poliovirus (PVS-RIPO) is an oncolytic virotherapy that gained public attention through a 2015 segment on 60 Minutes, highlighting its promising results in a phase I trial for recurrent glioblastoma at Duke University, where two patients achieved complete response and remained alive and progression-free for over two years. However, further findings indicated that dose escalation did not enhance efficacy, leading to the use of smaller doses in subsequent treatments.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:46:21Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:46, 12 November 2024
Line 3:		Line 3:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Genetically modified Poliovirus (PVS-RIPO)		\|drug_name=Genetically modified Poliovirus (PVS-RIPO)
	\|~~category~~=Oncolytic virotherapy		\|treatment_category=Oncolytic virotherapy
	\|book_text=In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost		\|book_text=In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost
	in public interest when an episode of the television show 60 minutes was devoted to it.		in public interest when an episode of the television show 60 minutes was devoted to it.

Lazy: Created page with " {{TreatmentInfo |drug_name=Genetically modified Poliovirus (PVS-RIPO) |category=Oncolytic virotherapy |book_text=In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost in public interest when an episode of the television show 60 minutes was devoted to it. Most exceptionally, the first two patients treated in this study were complete responders. As of March 2015 (when the 60 minutes special aired) these two complete responders were st..."

2024-04-06T04:18:18Z

Created page with " {{TreatmentInfo |drug_name=Genetically modified Poliovirus (PVS-RIPO) |category=Oncolytic virotherapy |book_text=In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost in public interest when an episode of the television show 60 minutes was devoted to it. Most exceptionally, the first two patients treated in this study were complete responders. As of March 2015 (when the 60 minutes special aired) these two complete responders were st..."

New page

{{TreatmentInfo
|drug_name=Genetically modified Poliovirus (PVS-RIPO)
|category=Oncolytic virotherapy
|book_text=In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost
in public interest when an episode of the television show 60 minutes was devoted to it.
Most exceptionally, the first two patients treated in this study were complete responders.
As of March 2015 (when the 60 minutes special aired) these two complete responders
were still alive and progression-free at 33 and 34 months from treatment. 11 of 22
patients in the trial were still alive, though six of these patients were less than 6 months
from treatment. Importantly, dose escalation of PVS-RIPO failed to improve efficacy, and
the more recent patients in the trial are being treated with a smaller dose than the trial
originally started with. Read an interview with Darrel Bigner discussing this trial here.
}}